Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 21, 2021 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Upcoming Presentation of NX-5948 Preclinical Data at the EULAR 2021 Virtual Congress

SAN FRANCISCO, May 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that preclinical...
May 11, 2021 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics to Participate in Upcoming Investor Conferences

SAN FRANCISCO, May 11, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that members of...
April 13, 2021 16:01 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports First Quarter Fiscal 2021 Financial Results and Provides a Corporate Update

On track to initiate Phase 1 trials for four wholly owned drug candidates in 2021 Expanded Sanofi collaboration resulting in option exercise payment of $22 million Strong financial position after...
April 07, 2021 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Participation in the 20th Annual Needham Virtual Healthcare Conference

SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T....
March 16, 2021 09:31 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Collaboration for the Discovery of Novel Drugs to Treat Pediatric Cancers

Research focused on targeted degradation of MYCN for the potential treatment of neuroblastoma and medulloblastomaProgram is one of four in Alex’s Lemonade Stand Foundation-funded $18.5 million Crazy 8...
March 10, 2021 17:12 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Presentation of NX-1607 Preclinical Data at AACR

CBL-B inhibitor NX-1607 mediates anti-tumor activity through both T cells and NK cellsPreclinical tumor models support clinical development of NX-1607 as monotherapy or in combination with PD-1...
March 09, 2021 16:01 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the closing of...
March 09, 2021 07:30 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences

SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur...
March 04, 2021 20:01 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

SAN FRANCISCO, March 04, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the pricing of...
March 02, 2021 16:15 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Launch of Proposed Public Offering of Common Stock

SAN FRANCISCO, March 02, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has...